Quidelortho Corp
QDEL.O- Latest Trade
- trading higher100.62USD
- Change
- 0.44
- % Change
0.44%Positive
- Day Range
- 99.56 - 101.08
- 52-Week Range
- 88.05 - 180.06
As of Jun 27 2022. Values delayed up to 15 minutes
- Previous Close
- 100.18
- Open
- 100.73
- Volume
- 19,606.00
- 3 Month Average Trading Volume
- 13.86
- Shares Out (Mil)
- 66.93
- Market Cap
- 6,704.98
- Forward P/E
- 6.46
- Dividend Yield
- -99,999.99
Key Statistics
2 mean rating - 5 analysts
- P/E Excl. Extra Items (TTM)
- 4.27
- Price To Sales (TTM)
- 2.88
- Price To Book (Quarterly)
- 1.74
- Price To Cash Flow (Per Share TTM)
- 6.30
- Total Debt/Total Equity (Quarterly)
- 0.00
- Long Term Debt/Equity (Quarterly)
- 0.00
- Return On Investment (TTM)
- 46.46
- Return On Equity (TTM)
- 38.77
2021 (millions USD)
About Quidelortho Corp
Company Information
QuidelOrtho Corporation is a vitro diagnostics company. The Company is engaged in the development and manufacturing of advanced technologies in diagnostic testing. Its product portfolio covers a range of point-of-care tests for infectious diseases, critical cardiac health and autoimmune biomarkers, and a range of clinical and at-home products to detect COVID-19. The Company’s capabilities include immunoassay development, automated manufacturing, monoclonal antibody characterization and development, molecular assay development, lab-based in vitro diagnostics, blood bank solutions and transfusion pre-screening. Its product categories include visually-read lateral flow, direct fluorescent antibodies, micro-titer production, fluorescent immunoassay products, molecular diagnostic products including its flagship Savanna, immunodiagnostics and integrated testing systems, pre-transfusion testing, immunodiagnostic donor screening systems and services, and ortho care services and informatics.
Address
9975 Summers Ridge RoadSAN DIEGO, CA
92121
United States
Industry
Healthcare Facilities
Executive Leadership
- Kenneth F. Buechler
- Independent Chairman of the Board
- Douglas C. Bryant
- President, Chief Executive Officer, Director
- Randall J. Steward
- Chief Financial Officer
- Robert Joseph Bujarski
- Chief Operating Officer
- Michelle A. Hodges
- Senior Vice President, General Counsel
- William J. Ferenczy
- Senior Vice President - Cardiometabolic Business Unit
- Karen C. Gibson
- Senior Vice President - Digital Health Business Unit
- Werner E. Kroll
- Senior Vice President - R&D
- Tamara A. Ranalli
- Senior Vice President - Molecular Business
- Edward Keith Russell
- Senior Vice President - Business Development
- Edward L. Michael
- Independent Director
- Mary Lake Polan
- Independent Director
- Ann D. Rhoads
- Independent Director
- Matthew W. Strobeck
- Independent Director
- Kenneth Jon Widder
- Independent Director
- Joseph D. Wilkins
- Independent Director
Latest News
- MarketsWalmart, Crocs, Alibaba
Wall Street's main indexes eased in choppy trading on Friday, but headed for their best three year run since 1999, driven by massive stimulus, vaccine rollouts, and strong retail participation.
- MarketsDeals of the day Mergers and acquisitions
The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Thursday:
- MarketsQuidel to buy Ortho Clinical for $6 bln to boost diagnostics portfolio
COVID-19 test maker Quidel Corp agreed to buy Ortho Clinical Diagnostics Holdings for about $6 billion in a cash and stock deal, less than a year since the Carlyle-backed firm went public.
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,822.90 | 0.20%Negative |
| Copper | 700.00 | 1.18%Positive |
| Brent Crude Oil | 114.59 | 1.30%Positive |
| CBOT Soybeans | 1,630.25 | 1.21%Positive |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 3,914.13 | 0.06%Positive |
| Euro STOXX 50 | 3,538.88 | 0.16%Positive |
| FTSE 100 | 7,258.32 | 0.69%Positive |
| Nikkei 225 | 26,871.27 | 1.43%Positive |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes